Inspiring transformational change in the

field of oncology diagnostics


To develop and deliver accurate, rapid, minimally

invasive oncology diagnostic products utilising our

patented MCM5 antibodies

Arquer Diagnostics is focused on the development and commercialisation of highly accurate minichromosome maintenance (MCM) protein based non-invasive tests for cancer diagnosis and monitoring.
Arquer aim to meet demand expressed by patients, clinicians and payers for cost-effective healthcare technologies that not only enhance patient care but help to reduce overall healthcare costs by improving patient outcomes.

Latest News


- 13 hours ago

Did you spot Arquer's CEO, Nadia Whittley, at the #ArquerDiagnostics stand at #EAU18 over the weekend? #Arquer…

- 1 day ago

Brush up on your knowledge and find out how you can get involved with #ProstateCancer Awareness Month by visiting t…

- 2 days ago

In as little as 3 hours, #ADXBLADDER can provide very accurate and reliable diagnostic results. Find out more about…